Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Monotherapy and in Combination With Tremelimumab vs SoC in First-Line Stage IV Urothelial Cancer
NCT02516241Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 24
01
Overview
A Phase 3 trial of durvalumab in urothelial carcinoma (UC), sponsored by AstraZeneca. Started Nov 2015; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02516241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516241.